Warning: The NCBI web site requires JavaScript to function. more...
High mobility group box-1 protein as a tumor necrosis factor-independent therapeutic target in rheumatoid arthritis.
Goldstein RS.
Arthritis Res Ther. 2008;10(3):111. Epub 2008 Jun 2.
Related citations
Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.
Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S, Ulfgren AK, Harris HE, Andersson U.
Arthritis Res Ther. 2008;10(2):R33. Epub 2008 Mar 17.
HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis.
Andersson U, Tracey KJ.
Rheum Dis Clin North Am. 2004 Aug;30(3):627-37, xi. Review.
Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sama AE, D'Amore J, Ward MF, Chen G, Wang H.
Acad Emerg Med. 2004 Aug;11(8):867-73. Review.
High mobility group box-1 as a therapeutic target downstream of tumor necrosis factor.
Czura CJ, Yang H, Tracey KJ.
J Infect Dis. 2003 Jun 15;187 Suppl 2:S391-6.
[Expression of high mobility group box chromosomal protein 1 in peripheral blood of patients with rheumatoid arthritis].
Zuo XX, Zhou YO, Gong YH, Wang YP, Tang DL, Xiao XZ.
Zhonghua Nei Ke Za Zhi. 2007 Jul;46(7):547-50. Chinese.
[The plasmic translocation and release of high mobility group box chromosomal protein 1 in peripheral blood monocytes of patients with rheumatoid arthritis and the effect of thalidomide].
Zuo XX, Gong YH, Zhou YO, Luo H, Xiao XZ.
Zhonghua Nei Ke Za Zhi. 2008 May;47(5):374-7. Chinese.
HMGB1 is a potent trigger of arthritis.
Andersson U, Erlandsson-Harris H.
J Intern Med. 2004 Mar;255(3):344-50. Review.
Cholinergic anti-inflammatory pathway activity and High Mobility Group Box-1 (HMGB1) serum levels in patients with rheumatoid arthritis.
Goldstein RS, Bruchfeld A, Yang L, Qureshi AR, Gallowitsch-Puerta M, Patel NB, Huston BJ, Chavan S, Rosas-Ballina M, Gregersen PK, Czura CJ, Sloan RP, Sama AE, Tracey KJ.
Mol Med. 2007 Mar-Apr;13(3-4):210-5.
Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling.
Pullerits R, Jonsson IM, Kollias G, Tarkowski A.
Arthritis Res Ther. 2008;10(3):R72. Epub 2008 Jun 26.
[Role of HMGB1 in rheumatic diseases].
Zhou JG, Zheng M.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Jul;36(4):412-6. Review. Chinese.
High mobility group box 1 in the pathogenesis of inflammatory and autoimmune diseases.
Voll RE, Urbonaviciute V, Herrmann M, Kalden JR.
Isr Med Assoc J. 2008 Jan;10(1):26-8. Review.
The relationship between cancer and rheumatoid arthritis: still a large research agenda.
Love T, Solomon DH.
Arthritis Res Ther. 2008;10(3):109. Epub 2008 May 14.
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.
Taylor PC, Feldmann M.
Nat Rev Rheumatol. 2009 Oct;5(10):578-82. Review.
Dealing with death: HMGB1 as a novel target for cancer therapy.
Lotze MT, DeMarco RA.
Curr Opin Investig Drugs. 2003 Dec;4(12):1405-9. Review.
Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.
Segal B, Rhodus NL, Patel K.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Dec;106(6):778-87. Epub 2008 Oct 19. Review.
High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis.
Ulloa L, Batliwalla FM, Andersson U, Gregersen PK, Tracey KJ.
Arthritis Rheum. 2003 Apr;48(4):876-81. Review. No abstract available.
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
Arthritis Rheum. 2008 Aug;58(8):2257-67.
Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients.
Li S, Kaur PP, Chan V, Berney S.
Clin Rheumatol. 2009 Jul;28(7):787-91. Epub 2009 Mar 17.
Tumor necrosis factor as a therapeutic target of rheumatologic disease.
Ackermann C, Kavanaugh A.
Expert Opin Ther Targets. 2007 Nov;11(11):1369-84. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on